Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session 1: Gastrointestinal tumours

91MO - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study

Date

02 Dec 2023

Session

Mini oral session 1: Gastrointestinal tumours

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Yasutoshi Kuboki

Citation

Annals of Oncology (2023) 34 (suppl_4): S1502-S1519. 10.1016/annonc/annonc1378

Authors

Y. Kuboki1, F. Pietrantonio2, L. Salvatore3, T. Esaki4, D.P. Modest5, D. Paez6, J. Taieb7, E. Ruiz8, T.W. KIM9, F.A. Meriggi10, D. Cunningham11, K. Yeh12, E. Chan13, J. Chao14, N. Strydom15, Y. Saportas16, Q. Tran17, C. Cremolini18, M. Fakih19

Author affiliations

  • 1 Experimental Therapeutics And Gi Oncology Department, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Dipartimento Di Oncologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 - Rome/IT
  • 4 Medical Oncology, National Hospital Organization Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 5 Medicine Department Of Hematology, Oncology And Tumorimmunology, Charité - Universitaetsmedizin Berlin, 13353 - Berlin/DE
  • 6 Dept. Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 7 Gastroenterology And Digestive Oncology Department, Hopital European George Pompidou, 75015 - Paris/FR
  • 8 Gi Oncology Department & Translational Medicine Laboratory, INCAN - Instituto Nacional de Cancerologia, 14080 - Ciudad de Mexico/MX
  • 9 Oncology Department, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 10 Oncology Department, Fondazione Poliambulanza Istituto Ospedaliero, 25124 - Brescia/IT
  • 11 Medicine Dept., The Institute of Cancer Research and Royal Marsden Hospital, SM2 5PT - Sutton/GB
  • 12 Department Of Oncology, NTUH - National Taiwan University Hospital, 10002 - Taipei City/TW
  • 13 Global Development, Amgen Inc., 91320 - Thousand Oaks/US
  • 14 Oncology Therapeutic Area, AMGEN - USA, 98119 - Seattle/US
  • 15 Clinical Pharmacology, Amgen Inc - SSF, 94080 - South San Francisco/US
  • 16 Global Safety, AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 17 Biostatistics, AMGEN (Headquarters) - USA, 91320-1799 - Thousand Oaks/US
  • 18 Polo Oncologico, AOU Pisana - Stabilimento di Santa Chiara, 56126 - Pisa/IT
  • 19 Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US

Resources

This content is available to ESMO members and event participants.

Abstract 91MO

Background

We report the first phase 3 primary results for sotorasib (soto), a KRASG12C-inhibitor, plus panitumumab (pani), an anti-EGFR antibody, vs standard of care (SOC) in patients (pts) with chemorefractory KRAS G12C-mutated mCRC.

Methods

In the CodeBreaK 300 (NCT05198934) global, open label study, 160 pts with chemorefractory KRAS G12C-mutated mCRC were randomized 1:1:1 to soto 960 mg daily plus pani 6 mg/kg IV (soto960+pani; n=53), soto 240 mg daily plus pani 6 mg/kg IV (soto240+pani, n=53), or investigator’s choice of TAS-102 or regorafenib (n=54). Primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) per RECIST 1.1. Key secondary endpoints included ORR, DRR, and DCR.

Results

The study met its primary endpoint. Both soto+pani arms demonstrated statistically significant superior PFS compared to SOC: soto960+pani HR=0.49 (95% CI: 0.30, 0.80; p=0.006), and soto240+pani HR=0.58 (95% CI: 0.36, 0.93; p=0.03). Secondary efficacy endpoints are shown in the table. OS was immature at data cutoff. Grade ≥3 TRAEs that occurred in ≥5% pts were dermatitis acneiform (11.3%), hypomagnesaemia (5.7%), and rash (5.7%) for soto960+pani; hypomagnesaemia (7.5%), diarrhoea (5.7%) for soto240+pani; and neutropenia (23.5%), anaemia (5.9%), and hypertension (5.9%) for SOC. There were no fatal TRAEs. Table: 91MO

Efficacy by BICR

Soto960+Pani n=53 Soto240+Pani n=53 SOC n=54
Median PFS, months (95% CI) 5.6 (4.21, 6.31) 3.9 (3.71, 5.75) 2.2 (1.94, 3.91)
ORR, % (95% CI) 26.4 (15.3, 40.3) 5.7 (1.2, 15.7) 0 (0.0, 6.6)
Number of responders 14 3 0
Median DOR, months (range) 4.4 (1.9+, 6.0+) NR (1.8+, 3.8+) --
DCR, % (95% CI) 71.7 (57.7, 83.2) 67.9 (53.7, 80.1) 46.3 (32.6, 60.4)

CI, confidence interval; DCR, disease control rate; DOR, duration of response; NR = not reached; ORR, objective response rate

Conclusions

In the first phase 3 study for a KRASG12C-inhibitor plus an anti-EGFR antibody in chemorefractory mCRC, the primary endpoint was met and both doses of soto+pani showed superior PFS vs SOC. Soto960+pani demonstrated clinically meaningful benefit across PFS and key secondary endpoints (ORR, DCR, DOR) and was tolerable with lower rates of Grade ≥3 TRAEs vs SOC.

Clinical trial identification

NCT05198934.

Editorial acknowledgement

Medical writing support was provided by Christopher Nosala (Amgen Inc.).

Legal entity responsible for the study

Amgen Inc.

Funding

Amgen Inc.

Disclosure

Y. Kuboki: Financial Interests, Personal, Invited Speaker: Taiho, Lilly, Takeda; Financial Interests, Personal, Advisory Role: Incyte, Takeda, Boeringer, Amgen, Abbie; Financial Interests, Institutional, Research Grant: Taiho, Astellas, Lilly, Takeda, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, Incyte, Abbie, Amgen, Merck, Hengrui. F. Pietrantonio: Financial Interests, Personal, Advisory Board: Amgen, Merck-Serono, MSD, Bayer, Organon, Astellas; Financial Interests, Personal, Invited Speaker: Amgen, Merck-Serono, BMS, Lilly, Servier, Bayer, Pierre Fabre, AstraZeneca, Astellas; Financial Interests, Institutional, Research Grant: BMS, AstraZeneca, Incyte, Agenus. L. Salvatore: Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Personal, Advisory Role: Pierre Fabre, Merck, Amgen, Servier, Bayer, AstraZeneca, Incyte, GSK, MSD; Financial Interests, Personal, Invited Speaker: Takeda, Pierre Fabre, Merck, Amgen, Servier, Bayer, AstraZeneca, Incyte, GSK, MSD; Financial Interests, Personal, Advisory Board: Pierre Fabre, Merck, Amgen, Servier, Bayer, AstraZeneca, Incyte, GSK, MSD. T. Esaki: Financial Interests, Institutional, Funding: Chugai, Nihon Kayaku; Financial Interests, Institutional, Research Grant: Eisai, Bayer, Asahikasei Pharma, Astellas, Amgen, Biopharma, Parexel, Eli Lilly, Quintiles, Dainippon Sumitomo, Pfizer, Syneos Health Clinical, Daiichi Sankyo, IQVIA, Nihon Kayaku, Chugai, Ono, Novartis, MSD; Financial Interests, Personal, Invited Speaker: Chugai, Taiho, EP force, MSD, Daiichi Sankyo, Eli Lilly, Ono, Bristol. D.P. Modest: Financial Interests, Personal, Invited Speaker: Amgen, Servier, Merck, Onkowissen, MSD, BMS, AstraZeneca, Pierre Fabre, Lilly, Cureteq, GSK, Seagen, Medison, COR2ED, JE, 21up; Financial Interests, Personal, Advisory Board: Amgen, Servier, Merck, MSD, BMS, Incyte, Takeda, G1, Onkowissen, Pierre Fabre, AstraZeneca; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Coordinating PI: Servier. D. Paez: Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Personal, Advisory Role: Amgen, Novartis, BMS; Financial Interests, Personal, Invited Speaker: Amgen, Novartis, BMS. J. Taieb: Financial Interests, Personal, Advisory Board: MSD, Astellas, Merck, Servier, Pierre Fabre, Amgen, BMS, Novartis, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, BMS, Merck, MSD, Novartis; Non-Financial Interests, Personal, Leadership Role, President of the scientific committee of the ARCAD foundation until end 2022: ARCAD Foundation; Non-Financial Interests, Personal, Leadership Role, Chair of the ARCAD pancreas research group: ARCAD Foundation; Non-Financial Interests, Personal, Leadership Role, Member of the administrative council, the scientific committee, the executive board and responsible for the international relationships /partnership for FFCD in the prodige intergroup: Federation Francophone de Cancerologie Digestive (FFCD). E. Ruiz: Financial Interests, Personal, Advisory Board: Roche, Amgen, BMS, Bayer, Pfizer; Financial Interests, Personal, Invited Speaker: Roche, Merck, Astellas; Non-Financial Interests, Personal, Member: ASCO. T.W. Kim: Financial Interests, Institutional, Research Grant: Genentech. D. Cunningham: Financial Interests, Personal, Advisory Role: OVIBIO; Financial Interests, Institutional, Research Grant: Medimmune, Clovis, Eli Lilly, 4SC, Bayer, Celgene, Leap, Roche. K. Yeh: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, PhytoHealth, Novartis, Ono, Merck, AstraZeneca; Non-Financial Interests, Personal, Member: American Society of Clinical Oncology, American Association for Cancer Research. E. Chan, J. Chao, N. Strydom, Y. Saportas, Q. Tran: Financial Interests, Personal, Full or part-time Employment: Amgen Inc.; Financial Interests, Personal, Stocks/Shares: Amgen Inc. C. Cremolini: Financial Interests, Personal, Advisory Board: Roche, MSD, Amgen, Pierre Fabre, Nordic Pharma; Financial Interests, Personal, Invited Speaker: Bayer, Servier, Merck Serono; Financial Interests, Institutional, Coordinating PI: Roche, Bayer, Servier, Merck; Financial Interests, Institutional, Local PI: Seagen, Hutchinson. M. Fakih: Financial Interests, Personal, Advisory Board, Consultant: AstraZeneca, Bayer Corporation, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, One meeting: Eisai Oncology; Financial Interests, Personal, Advisory Board, One meeting: Entos, Merck, Seattle Genetics, Xenthera; Financial Interests, Personal, Advisory Board, Also Editorial Boards & Consulting: Mirati Therapeutics; Financial Interests, Personal, Advisory Board: Nouscom, Roche / Genentech; Financial Interests, Personal, Advisory Board, Consulting: Pfizer, Taiho Oncology; Financial Interests, Institutional, Research Grant: AgenusBio, Genentech / imCORE, Verastem. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.